FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International (OTCBB: OXIS; Nouveau Marche: OXIS) (FWB: OXI), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that it has retained Okezie Aruoma PhD, an internationally recognized expert on anti-oxidants and L-Ergothioneine (ERGO), to help the Company accelerate development of its portfolio of biomarkers and promote the launch and marketing of ERGO, the company’s potent antioxidant neutraceutical. Dr. Aruoma has 18 years of experience in biomedical research focused on food biofactors, oxidative stress mechanisms and antioxidant pharmacology and their pharmaceutical indications as prophylactic agents.
